Eterna Therapeutics Stock Current Valuation
| ERNA Stock | USD 1.02 0.05 4.67% |
Valuation analysis of Eterna Therapeutics helps investors to measure Eterna Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The current year's Enterprise Value is expected to grow to about 157.2 M, whereas Enterprise Value Over EBITDA is projected to grow to (2.13). Fundamental drivers impacting Eterna Therapeutics' valuation include:
Price Book 2.0975 | Enterprise Value 52.1 M | Enterprise Value Ebitda (0.29) | Price Sales 34.0667 | Enterprise Value Revenue 321.8444 |
Fairly Valued
Today
Please note that Eterna Therapeutics' price fluctuation is extremely dangerous at this time. Calculation of the real value of Eterna Therapeutics is based on 3 months time horizon. Increasing Eterna Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Eterna Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Eterna Stock. However, Eterna Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.02 | Real 0.99 | Hype 1.05 | Naive 1.07 |
The real value of Eterna Stock, also known as its intrinsic value, is the underlying worth of Eterna Therapeutics Company, which is reflected in its stock price. It is based on Eterna Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Eterna Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Eterna Therapeutics helps investors to forecast how Eterna stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Eterna Therapeutics more accurately as focusing exclusively on Eterna Therapeutics' fundamentals will not take into account other important factors: Eterna Therapeutics Company Current Valuation Analysis
Eterna Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Eterna Therapeutics Current Valuation | 52.14 M |
Most of Eterna Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eterna Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Eterna Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Eterna Therapeutics is extremely important. It helps to project a fair market value of Eterna Stock properly, considering its historical fundamentals such as Current Valuation. Since Eterna Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Eterna Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Eterna Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Eterna Current Valuation Historical Pattern
Today, most investors in Eterna Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Eterna Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Eterna Therapeutics current valuation as a starting point in their analysis.
Eterna Therapeutics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Eterna Therapeutics has a Current Valuation of 52.14 M. This is 99.64% lower than that of the Biotechnology sector and 98.88% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.69% higher than that of the company.
Eterna Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eterna Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eterna Therapeutics could also be used in its relative valuation, which is a method of valuing Eterna Therapeutics by comparing valuation metrics of similar companies.Eterna Therapeutics is currently under evaluation in current valuation category among its peers.
Eterna Fundamentals
| Return On Equity | -11.54 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (104.91) % | ||||
| Current Valuation | 52.14 M | ||||
| Shares Outstanding | 5.41 M | ||||
| Shares Owned By Insiders | 39.30 % | ||||
| Shares Owned By Institutions | 7.20 % | ||||
| Number Of Shares Shorted | 54.42 K | ||||
| Price To Book | 2.10 X | ||||
| Price To Sales | 34.07 X | ||||
| Revenue | 68 K | ||||
| EBITDA | (19.55 M) | ||||
| Net Income | (21.67 M) | ||||
| Cash And Equivalents | 19.41 M | ||||
| Cash Per Share | 6.60 X | ||||
| Total Debt | 41.84 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 3.08 X | ||||
| Book Value Per Share | (1.58) X | ||||
| Cash Flow From Operations | (20.41 M) | ||||
| Short Ratio | 1.01 X | ||||
| Earnings Per Share | (4.43) X | ||||
| Price To Earnings To Growth | (0.03) X | ||||
| Target Price | 3.0 | ||||
| Beta | 7.77 | ||||
| Market Capitalization | 5.52 M | ||||
| Total Asset | 49.13 M | ||||
| Retained Earnings | (186.98 M) | ||||
| Working Capital | 3.03 M | ||||
| Net Asset | 49.13 M |
About Eterna Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eterna Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eterna Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eterna Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| MSFT | Microsoft | |
| F | Ford Motor | |
| CRM | Salesforce |
Check out Eterna Therapeutics Piotroski F Score and Eterna Therapeutics Altman Z Score analysis. For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eterna Therapeutics. If investors know Eterna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eterna Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.43) | Revenue Per Share 0.03 | Return On Assets (0.29) | Return On Equity (11.54) |
The market value of Eterna Therapeutics is measured differently than its book value, which is the value of Eterna that is recorded on the company's balance sheet. Investors also form their own opinion of Eterna Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Eterna Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eterna Therapeutics' market value can be influenced by many factors that don't directly affect Eterna Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eterna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eterna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eterna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.